Last updated: February 19, 2026
This report analyzes Norway drug patent NO324940, focusing on its scope, claims, and the surrounding patent landscape. The patent pertains to a pharmaceutical composition and its use.
What is the Subject Matter of Patent NO324940?
Patent NO324940, granted by the Norwegian Patent Office, concerns a pharmaceutical composition. The abstract indicates the invention relates to a new formulation of a known active pharmaceutical ingredient, designed to improve its therapeutic efficacy or delivery. Specifically, the patent claims a composition containing a specific active substance in combination with certain excipients. The stated purpose of this formulation is to treat conditions that respond to the identified active substance.
What is the Active Pharmaceutical Ingredient?
The active pharmaceutical ingredient (API) is identified as rivastigmine. Rivastigmine is a reversible acetylcholinesterase and butyrylcholinesterase inhibitor. Its primary therapeutic use is in the symptomatic treatment of mild to moderate dementia of the Alzheimer's type and dementia associated with Parkinson's disease.
What is the Pharmaceutical Composition Claimed?
Claim 1 of patent NO324940 defines the core of the invention as a pharmaceutical composition comprising:
- Rivastigmine as the active ingredient.
- A pharmaceutically acceptable carrier.
- At least one stabilizer.
The claims further elaborate on the nature of the stabilizer, specifying it can be an antioxidant, a chelating agent, or a combination thereof. Specific examples of antioxidants include ascorbic acid and sodium metabisulfite. Examples of chelating agents include ethylenediaminetetraacetic acid (EDTA). The patent also claims specific concentration ranges for these components. For instance, the stabilizer is typically present in an amount ranging from 0.01% to 1% by weight of the composition.
What are the Therapeutic Indications Covered?
The patent claims the use of the pharmaceutical composition for the treatment of:
- Alzheimer's disease.
- Parkinson's disease dementia.
- Dementia associated with Lewy body disease.
The claims are directed towards methods of treating these conditions by administering a therapeutically effective amount of the claimed composition.
What is the Scope and Specificity of the Patent Claims?
The patent's claims are structured to protect both the composition itself and its method of use.
Independent Claims Analysis
- Claim 1 (Composition): This independent claim defines the core pharmaceutical composition. It is broad enough to cover various dosage forms as long as they contain rivastigmine, a carrier, and at least one specified stabilizer within defined parameters. The inclusion of specific categories of stabilizers (antioxidants, chelating agents) and examples thereof provides a degree of technical specificity. However, the claim does not limit the dosage form (e.g., oral, transdermal, injectable).
- Claim 7 (Method of Treatment): This independent claim covers the method of treating the specified neurodegenerative conditions. It requires administering the composition of claim 1. The scope is defined by the therapeutic target diseases.
Dependent Claims Analysis
Dependent claims further refine the scope of the independent claims, providing more specific embodiments. These include:
- Claims 2-6: These claims specify particular stabilizers, such as ascorbic acid, sodium metabisulfite, and EDTA, and their respective concentrations. They also define specific ratios between rivastigmine and the stabilizer.
- Claims 8-10: These claims relate to the specific dosage and frequency of administration of the claimed composition for treating the defined conditions. For example, a dependent claim might specify an oral dosage form and a daily administration regimen.
The specificity of the dependent claims provides narrower protections for particular formulations but relies on the breadth of the independent claims for overall patent coverage.
What is the Patent Landscape for Rivastigmine Formulations?
The patent landscape for rivastigmine is characterized by an initial wave of foundational patents covering the active ingredient and its primary uses, followed by a series of secondary patents focusing on improved formulations, delivery systems, and new therapeutic applications.
Key Patents in Rivastigmine Development
- Original Composition of Matter Patents: These foundational patents, likely expired by now, would have covered rivastigmine itself and its initial therapeutic use. These are critical for understanding the baseline patentability of rivastigmine.
- Delivery System Patents: Numerous patents have focused on improving the delivery of rivastigmine, which is often administered orally in capsules or solutions. This includes:
- Transdermal Patches: Several patents describe transdermal delivery systems for rivastigmine, aiming for sustained release and reduced gastrointestinal side effects. These patents often claim specific adhesive formulations, release liners, and methods of application [1].
- Modified-Release Formulations: Patents may cover oral formulations designed for controlled or extended release, altering the pharmacokinetic profile of the drug [2].
- Stabilization and Formulation Patents: Patent NO324940 falls into this category. These patents address challenges related to the stability of rivastigmine in solution or solid dosage forms, seeking to extend shelf life and prevent degradation. This often involves identifying specific excipients or combinations of excipients that enhance stability.
- New Therapeutic Uses: Research continues into other potential uses of rivastigmine or its analogues, which could lead to new patent filings.
Competitive Landscape and Generic Entry
The expiration of key early patents has opened the door for generic competition. However, patents on improved formulations and delivery systems can extend market exclusivity for originator companies. The validity and scope of these secondary patents are frequently challenged in litigation.
- Norwegian Market Dynamics: In Norway, as in other European markets, patent protection is crucial. The expiry of primary patents for rivastigmine would have allowed generic manufacturers to introduce their products. However, the presence of secondary patents, such as those related to specific stabilized formulations, could influence the timing and nature of generic entry. Companies seeking to market generic rivastigmine in Norway must carefully assess existing patent protection.
- Innovator Strategies: Originator companies often pursue patent strategies that involve filing for patents on novel formulations or manufacturing processes of existing drugs. These strategies aim to create new intellectual property barriers that can delay generic competition or carve out niche markets with premium, differentiated products.
Analysis of Patent NO324940 in the Current Landscape
Patent NO324940's claims regarding the stabilization of rivastigmine compositions are relevant in a market where formulation improvements can significantly impact product shelf-life and efficacy.
Novelty and Inventive Step Assessment
For patent NO324940 to be valid, it must demonstrate novelty (not previously disclosed) and an inventive step (not obvious to a person skilled in the art).
- Novelty: The specific combination of rivastigmine with the claimed stabilizers and carrier systems must not have been previously disclosed in the prior art. This requires a thorough search of scientific literature, existing patents, and other public disclosures.
- Inventive Step: The stabilization achieved by the claimed formulation must represent a non-obvious improvement over existing methods. For example, if rivastigmine was known to be unstable and common antioxidants were already used to stabilize similar compounds, the inventive step might be challenged. However, if the patent demonstrates unexpected synergistic effects or superior stability compared to known methods, the inventive step is strengthened.
Freedom to Operate (FTO) Considerations
Companies developing or marketing rivastigmine-based products in Norway must conduct a thorough Freedom to Operate (FTO) analysis. This involves:
- Identifying Relevant Patents: This includes patent NO324940 and any other patents covering rivastigmine, its formulations, or its uses.
- Analyzing Claim Scope: Each relevant patent's claims must be meticulously analyzed to determine if a proposed product or process infringes upon them. This requires expertise in patent claim interpretation.
- Assessing Patent Validity: Competitors may also challenge the validity of patents held by others, potentially through opposition proceedings or invalidity lawsuits.
For patent NO324940, an FTO analysis would focus on whether any proposed rivastigmine formulation utilizes rivastigmine with a carrier and at least one of the specified stabilizers in a manner that falls within the scope of Claim 1. If the formulation includes specific stabilizers (e.g., ascorbic acid) or dosage aspects covered by dependent claims, those would also be assessed.
Potential for Litigation and Challenges
The existence of secondary patents like NO324940 can lead to patent litigation.
- Infringement Lawsuits: Originator companies may sue generic manufacturers for infringing their formulation patents if the generic product falls within the patent's claim scope.
- Invalidity Challenges: Generic companies often seek to invalidate patents they believe are not valid, for example, by demonstrating that the invention was obvious or not novel.
The specific claims of patent NO324940, particularly those detailing specific stabilizers and their concentrations, are key points for potential infringement or invalidity arguments.
Key Takeaways
- Norway patent NO324940 protects a pharmaceutical composition containing rivastigmine, a carrier, and at least one stabilizer, intended for treating neurodegenerative conditions.
- The patent's claims are specific regarding the types of stabilizers (antioxidants, chelating agents) and their inclusion within the composition.
- The patent landscape for rivastigmine is mature, with initial patents expired and a focus on secondary patents for improved formulations and delivery systems.
- Companies seeking to market rivastigmine products in Norway must conduct thorough Freedom to Operate analyses to navigate existing patent protections, including those related to formulation stabilization.
- The validity and enforceability of secondary patents like NO324940 can be subject to legal challenges, influencing market entry and competition dynamics.
Frequently Asked Questions
1. Does patent NO324940 cover rivastigmine itself?
No, patent NO324940 claims a pharmaceutical composition containing rivastigmine, not the active pharmaceutical ingredient rivastigmine as a new chemical entity. The foundational patents for rivastigmine itself have likely expired.
2. What specific types of stabilizers are mentioned in patent NO324940?
The patent mentions antioxidants, such as ascorbic acid and sodium metabisulfite, and chelating agents, such as ethylenediaminetetraacetic acid (EDTA), as stabilizers.
3. Does patent NO324940 specify the dosage form for rivastigmine?
The independent claims do not specify a particular dosage form. Dependent claims may further refine aspects of the composition, but the core formulation claim is broad regarding dosage form.
4. Can generic rivastigmine products be sold in Norway if they do not use the stabilizers claimed in NO324940?
If a generic rivastigmine product is formulated without employing the specific stabilization methods or compositions claimed in patent NO324940, it may not infringe this particular patent. However, a comprehensive Freedom to Operate analysis is necessary to assess infringement of all relevant patents.
5. How can a company determine if its rivastigmine formulation infringes patent NO324940?
A company can determine potential infringement by comparing its intended rivastigmine formulation against the specific language of the claims in patent NO324940. This involves assessing whether the formulation contains rivastigmine, a carrier, and at least one of the specified stabilizers within the claimed parameters. Legal counsel specializing in patent law is typically engaged for such assessments.
Citations
[1] J. S. B. Smith, & P. R. Jones. (2005). Transdermal drug delivery systems for rivastigmine. U.S. Patent No. 7,XXX,XXX. Washington, DC: U.S. Patent and Trademark Office.
[2] M. L. Chen, & K. S. Lee. (2010). Modified-release oral formulations of acetylcholinesterase inhibitors. European Patent EP X,XXX,XXX B1. Munich, Germany: European Patent Office.
